Jiangsu Hengrui Pharmaceuticals (01276): Certain products included in the 2026 National Medical Insurance Catalog
Jiangsu Hengrui Pharmaceuticals (01276) announced that certain of the Company's products have been included in the 2026 National Medical Insurance Catalog.
Jiangsu Hengrui Pharmaceuticals (01276) announced that certain of the company's products have been included in the 2026 National Medical Insurance Catalog.
Through medical insurance negotiations, Zemrelstat Tablets, Luznorelin Sodium Tablets, and Henggliflozin/Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (II) were included in the National Medical Insurance Catalog for the first time; the new indication for Riconcartuzumab Injection was successfully included in the National Medical Insurance Catalog; Darcilide Ethanesulfonate Tablets successfully renewed and a new indication was included in the National Medical Insurance Catalog; Proline Henggliflozin Tablets, Revenirutamide Tablets, Tegilidine Fumarate Injection, Oteseconazole Capsules, Henggliflozin/Metformin Extended-Release Tablets (I)/(II), Camrelizumab for Injection, and Pregabalin Extended-Release Tablets successfully renewed and remained in the National Medical Insurance Catalog.
Related Articles

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.
GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.






